Clinical Trials | August 04, 2022
Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Steps afoot to make RRIH & RRIUM as a Centres of Excellence for Allergic Disorder and for Regimental Therapy respectively
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
72.5% elderly feel their generation used to spend more time with their elders, 52.4% feel lonely, shows PAN Health’s Liberty in Life of Older People 2022 survey
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
She joins Enveda from Gilead Sciences
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
Transcatheter Mitral valve procedure allows intervention on patients who are unsuitable or high risk for open heart surgery
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
